Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70616 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Simone I Strasser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Primary biliary cholangitis (PBC) is an autoimmune liver disease that targets the small intrahepatic bile ducts with diagnosis based on elevated serum alkaline phosphatase (ALP) levels and the presence of anti‐mitochondrial antibodies. Untreated, it may run a progressive course to cirrhosis and hepatic decompensation, at which point liver transplantation is the only effective treatment. This review provides discussion of PBC treatment goals in the Australian context. People with PBC often experience a quality of life burden characterized by fatigue and itch. Extra‐hepatic associations may include osteoporosis, Sjögren's syndrome, and thyroid dysfunction. Established baseline risk factors for progression are male gender, young age at onset (< 45 years), ALP > 1.5 × upper limit of normal (ULN), presence of anti‐gp210 antibodies, and significant liver fibrosis at diagnosis. Ursodeoxycholic acid (UDCA) is the mainstay of therapy and improves outcomes including transplant‐free survival. Patients with inadequate response to UDCA (about 40%), disease progression, or bothersome symptoms require additional second‐line (2L) therapy. Second‐line treatments include selective peroxisome proliferator‐associated receptor (PPAR) agonists, obeticholic acid (OCA; subject to precautions), and off‐label use of fenofibrate. In Australia, reimbursement for 2L therapies relies on ALP ≥ 1.67 × ULN or total bilirubin between 1 and 2 × ULN after 1 year of UDCA therapy. Normalization of ALP is an aspirational treatment target with increasing evidence for improved outcomes. Proactive and diligent monitoring of patients with PBC allows personalized selection and early initiation of effective and well‐tolerated 2L therapies with potential for improved outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
- University of Sydney, Camperdown, New South Wales, Australia.
- St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia.
- University of Melbourne, Melbourne, Victoria, Australia.
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
- Alfred Health Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Simone I Strasser, Alexander J Thompson, Rohit Gupta, John Lubel, Janine French, Martin Weltman
Förderung
- Gilead Sciences
Zitieren
APA
Strasser, S. I., Thompson, A. J., Gupta, R., Lubel, J., French, J., Sacks, B., & Weltman, M. (2026). Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70616
Vancouver
Strasser SI, Thompson AJ, Gupta R, Lubel J, French J, Sacks B, et al. Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70616
BibTeX
@article{Strasser2026,
author = {Strasser, Simone I and Thompson, Alexander J and Gupta, Rohit and Lubel, John and French, Janine and Sacks, Beverly and Weltman, Martin},
title = {Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70616}
}
EUVIMED